Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7212505 | 0.93 | NPSR1 (0.42) | NPSR1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL7217326 | 0.84 | KCNN4 (0.48) | SMN1; SMN2KMT2AKCNN4ALDH1A1 | |
| SCHEMBL4590400 | 0.78 | MAPT (0.50) | NPSR1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL7217207 | 0.77 | KCNN4 (0.46) | SMN1; SMN2KMT2AKCNN4ALDH1A1S1PR1 | |
| Hydroxyphenamate SCHEMBL546919 | 0.74 | KMT2A (0.42) | NPSR1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| Hydroxyphenamate SCHEMBL5704281 | 0.74 | KMT2A (0.42) | NPSR1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| Urethane SCHEMBL3680047 | 0.70 | ALOX15 (0.56) | NPSR1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL28188464 | 0.69 | MAPT (0.48) | CYP1A2CYP2D6MAPTKMT2AKCNN4 | |
| Benzyl Carbamate SCHEMBL27962908 | 0.69 | ALDH1A1 (0.52) | LMNAKMT2AMAPK1CA1CA2 | |
| SCHEMBL5012067 | 0.68 | TSHR (0.52) | NPSR1CYP1A2LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1156798-B1 | FELBAMATE DERIVED COMPOUNDS | UNIV VIRGINIA (US) | 2003-07-09 | — | — | EP | claimed |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240382452-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240065988-A1 | COMBINED USE OF KETAMINE AND RETIGABINE (EZOGABINE) FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-02-29 | — | — | US | disclosed |
| US-20230405021-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | MARINUS PHARMACEUTICALS, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11679117-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2023086343-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11523986-B2 | Intranasally administered antihistamines and uses thereof | DBBH, LLC (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220265680-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC. | 2022-08-25 | — | — | US | disclosed |
| CN-114728012-A | Ganaxolone for the treatment of status epilepticus | 马瑞纳斯制药公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220202831-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC. | 2022-06-30 | — | — | US | disclosed |
| EP-4009982-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | Marinus Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11357793-B2 | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration | SAPNA LIFE SCIENCES CORPORATION (CA) | 2022-06-14 | — | — | US | disclosed |
| US-20220160656-A1 | INTRANASALLY ADMINISTERED ANTIHISTAMINES AND USES THEREOF | DBBH, LLC | 2022-05-26 | — | — | US | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | NPSR1 600/4885CYP1A2 2739/4885CYP2D6 4108/4885 |
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | NPSR1 967/4885CYP1A2 31/4885CYP2D6 164/4885 |
| US-20220265680-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP21A2, CYP17A1, HSD17B11 | NPSR1 967/4885CYP1A2 31/4885CYP2D6 164/4885 |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP4A11, CYP21A2, CYP17A1 | NPSR1 2678/4885CYP1A2 25/4885CYP2D6 86/4885 |
| US-11679117-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | NPSR1 967/4885CYP1A2 31/4885CYP2D6 164/4885 |
| US-20220202831-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP21A2, CYP17A1, HSD17B11 | NPSR1 967/4885CYP1A2 31/4885CYP2D6 164/4885 |
| US-20230405021-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP21A2, CYP17A1, HSD17B11 | NPSR1 967/4885CYP1A2 31/4885CYP2D6 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.